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Summary
Background and objectives Congenital anomalies of the kidney and urinary tract (CAKUT) are the leading cause of
ESRD in children, but the proportion of patients with individual CAKUT entities progressing to ESRD during
adulthood and their long-term clinical outcomes are unknown. This study assessed the age at onset of renal
replacement therapy (RRT) and patient and renal graft survival in patientswith CAKUT across the entire age range.
Design, setting, participants, & measurements Patients with CAKUT were compared with age-matched patients
who were undergoing RRT for other renal disorders on the basis of data from the European Renal Association-
European Dialysis and Transplant Association Registry. Competing risk and Cox regression analyses were
conducted.
Results Of 212,930 patients commencing RRT from 1990 to 2009, 4765 (2.2%) had renal diagnoses consistent with
CAKUT. The proportion of incident RRT patients with CAKUT decreased from infancy to childhood and then
increased until age 15–19 years, followed by a gradual decline throughout adulthood.Median age at RRT start was 31
years in the CAKUT cohort and 61 years in the non-CAKUT cohort (P,0.001). RRT was started earlier (median, 16
years) in patients with isolated renal dysplasia than in those with renal hypoplasia and associated urinary tract dis-
orders (median, 29.5–39.5 years). Patients with CAKUT survived longer than age- and sex-matched non-CAKUT
controls because of lower cardiovascular mortality (10-year survival rate, 76.4% versus 70.7%; P,0.001).
ConclusionsCAKUT leads to ESRDmore often at adult than pediatric age. Treatment outcomes differ from those
of acquired kidney diseases and vary within CAKUT subcategories.
Clin J Am Soc Nephrol 8: 67–74, 2013. doi: 10.2215/CJN.03310412
Introduction
Congenital anomalies of the kidney and urinary tract
(CAKUT) are the most common cause of ESRD in
children. Bilateral renal hypoplasia and dysplasia with
orwithout concomitanturinary tractmalformationsare
present in more than 50% of children and adolescents
commencing renal replacement therapy (RRT) (1–5). In
contrast, CAKUT is amuch less common cause of ESRD
in adult patients undergoing RRT, accounting for less
than 5% of a disease spectrum dominated by diabetic
and nondiabetic glomerulopathies (6–9).
The natural course of CAKUT is very heterogeneous
(10,11). Although the most severely affected new-
borns progress to ESRD within the ﬁrst few months
of life, kidney function improves in most children
born with CAKUT, typically reaching a peak around
age 3–4 years. Subsequently, kidney function remains
stable in most children until puberty. During adoles-
cence, accelerated progression of CKD to ESRD is fre-
quently observed (10). Altogether, approximately
25% of children born with bilateral CAKUT and kid-
ney dysfunction require RRT during the ﬁrst two
decades of life (2,10,11). However, little information
is available about the long-term prognosis of patients
with CAKUT as they advance into adult life.
The aim of this study was to assess the demo-
graphic characteristics of patients with CAKUT who
were starting RRT and their outcomes on RRT across all
agegroupscomparedwithpatientswithoutCAKUT.We
used the database of the European Renal Association-
European Dialysis and Transplant Association (ERA-
EDTA)Registry, a large longitudinaldatabaseofpatients
receivingRRTthroughoutEuropethat includescomplete
patient-level information from 12 countries with 150
million European residents.
Methods
Patient Population
Data on the incidence of RRT, time on dialysis, renal
allograft, and patient survival in patients with CA-
KUT were extracted from the ERA-EDTA Registry.
The diagnosis CAKUT comprised the following
ERA-EDTA primary renal disease codes (6): con-
genital renal hypoplasia (“hypoplasia”; code 60),
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oligomeganephronic hypoplasia (code 61), congenital re-
nal dysplasia with or without urinary tract malformation
(“dysplasia”; code 63), syndrome of agenesis of abdominal
muscles (prune belly syndrome; code 66), pyelonephritis
associated with neurogenic bladder (“neurogenic pyelone-
phritis”; code 21), pyelonephritis due to congenital ob-
structive uropathy with or without vesico-ureteric reﬂux
(“obstructive pyelonephritis”; code 22), and pyelonephritis
due to vesico-ureteric reﬂux without obstruction (“reﬂux
pyelonephritis”; code 24). The few patients coded as
“prune belly syndrome” (code 66) were combined with
code 63, whereas patients with “oligomeganephronia”
(code 61) were combined with code 60 for further analysis.
Patients with “pyelonephritis cause not speciﬁed” (code
20), “pyelonephritis due to acquired obstructive uropathy”
(code 23), “pyelonephritis due to urolithiasis” (code 25),
and “pyelonephritis due to other cause” (code 29) were not
included in the analysis.
Incidence and prevalence data on patients with CAKUT
from countries providing patient data from birth onward to
the ERA-EDTA registry were analyzed (Austria, Denmark,
Andalusia [Spain], Asturias [Spain], Basque country
[Spain], Canary Island [Spain], Castille and Leon [Spain],
Castile-La Mancha [Spain], Catalonia [Spain], Extremadura
[Spain], Galicia [Spain], Valencian region [Spain], Finland,
France, Greece, Iceland, the Netherlands, Norway, Roma-
nia, Sweden, and Scotland). The observation period was
restricted to 1990–2009 but differed by country.
Incidence and prevalence data as well as age-dependent
patterns of onset of RRTwere analyzed with respect to patient
survival, time on dialysis, and ﬁrst renal allograft survival.
For comparison of patient and graft survival on RRT, two
control groups (one for dialysis and one for graft survival) of
patients with other underlying renal diagnoses matched
for age, sex, country, year of start of RRT, and initial RRT
modality were randomly selected from the registry. Further-
more, the CAKUT and non-CAKUT control patients did not
differ with respect to the time on dialysis before transplan-
tation and the proportion of pre-emptive transplantations.
The underlying primary renal diseases in the matched
controls were glomerulonephritis (27.2%), diabetic ne-
phropathy (11.9%), hypertension or renovascular disease
(7.8%), and cystic kidney disease (9.7%). In 26.8%, other
causes of ESRD were speciﬁed, and in 16.6% the renal
disease was not classiﬁed.
Statistical Analyses
Incidence was deﬁned as the number of patients with
CAKUT starting RRT in the study period; point prevalence
was deﬁned as the total number of patients undergoing
RRT on December 31, 2009. Both incidence and prevalence
were expressed as absolute numbers and per million age-
related population. EUROSTAT (the statistical ofﬁce of
the European Union), the national bureau of statistics, or
the contributing national or regional registries provided the
general population data. To investigate trends over time,
the time periods 1990–1999 and 2000–2009 were compared.
The risk for death from speciﬁc causes was calculated as
incidence per person time on RRT, and 95% conﬁdence
intervals were used to assess statistically signiﬁcant differ-
ences. All matched controls from both cohorts were used
for comparison.
For the time-to-event data analysis for patient survival
on dialysis or graft survival, a competing risk analysis was
performed (12). P values to test for signiﬁcance were cal-
culated according to the method of Pepe and Mori (13).
Cox regression models were used to analyze differences
in patient and graft survival between subgroups. All analy-
ses were adjusted for age, sex, cause of ESRD, RRT modal-
ity, period of RRT, and country of residence. All statistical
analyses were performed using SAS software, version 9.2
(SAS Institute Inc., Cary, NC). P values ,0.05 were consid-
ered to represent statistically signiﬁcant ﬁndings.
Results
Patient Characteristics
From January 1, 1990, to December 31, 2009, a total of
212,930 patients started RRT in the area of the contributing
registries. Of these, 4765 patients were classiﬁed as
having a diagnosis of CAKUT. In the ERA-EDTA Registry
population, CAKUT is a relatively rare diagnosis, account-
ing for 2.2% of the total patient cohort (Table 1). The in-
cidence of RRT due to CAKUT disorders was stable over
time (2.6–3.0 per million age-related population in any
5-year period between 1990 and 2009).
The median age at start of RRT was 31 years in patients
with CAKUT and 61 years in the total ERA-EDTA Registry
cohort. The incidence ofRRTwas lowest at age 5–9years and
increased to maximum around age 15–19 years, followed
by a gradual decline throughout adulthood (Figure 1). In
contrast, the number of patients with other primary renal
diagnoses who started RRT increased steadily with age.
Regarding the number of patients starting RRT in
different age categories in 2000–2009 compared with
1990–1999, there was a clear tendency toward initiating
RRT in more elderly patients. However, the number of
young patients starting RRT did not change signiﬁcantly
over time.
Male patients with CAKUTwere signiﬁcantly younger at
RRT start than female patients (mean difference, 5.2 years).
However, this effect differed according to the type of
CAKUT. Although male patients with obstructive (mean
age, 31.5 years) or reﬂux (35.1 years) pyelonephritis were
signiﬁcantly younger than female patients (40.6 and 41.9
years, respectively; P,0.001), the age at start of RRT did
not differ by sex in patients with renal dysplasia or hypo-
plasia. Women with neurogenic pyelonephritis initiated
RRT at an even younger age than men (37.0 versus 44.7
years; P,0.001).
Irrespective of sex, patients with dysplasia required RRT
at a signiﬁcantly younger age than patients in the other
CAKUT categories (Figure 2).
Prevalence and Incidence of RRT in Patients with CAKUT
The point prevalence of RRT on December 31, 2009, was
947.5 cases per million population for the total ERA-EDTA
Registry cohort and 44.9 cases per million population for
patients with CAKUT. During the ﬁrst decade of life the
incidence of RRT for ESRD due to renal dysplasia was
highest (1.2 per million age-related population) (Figure
2A), followed by obstructive pyelonephritis (0.8 per mil-
lion age-related population) and hypoplasia (0.5 per mil-
lion age-related population). Kidney failure due to reﬂux
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pyelonephritis requiring RRT increased steeply in inci-
dence during the ﬁrst two decades, peaking (1.7 per mil-
lion age-related population) in the early twenties.
Obstructive pyelonephritis resulted in a similar maximum
RRT incidence in early adult life (1.5 per million age-
Figure 1. | Age distribution at onset of renal replacement therapy
(RRT). Percentage of patientswith congenital anomalies of the kidney
and urinary tract (CAKUT) (closed bars) starting RRT at a given age
compared with groups with non-CAKUT primary renal disease
(hatched bars) in the European Renal Association-European Dialysis
and Transplant Association registry.
Figure 2. | Incidence and cumulative percentage of patients starting
renal replacement therapy (RRT) by subcategory of congenital
anomalies of the kidney and urinary tract (CAKUT). (A) Incidence
per million age-related population. (B) Cumulative percentage.
Table 1. Characteristics of patients receiving renal
replacement therapy in the European Renal Association-
European Dialysis and Transplant Association Registry between
January 1, 1990, and December 31, 2009
Characteristic AllPatients
Patients
with
CAKUT
Prevalence 2009 (pmp) 947.5 44.9
Incidence (n) 212,930 4,765
Male patients (%) 61.5 61.5
Renal diagnoses (%)
Hypertensive or
diabetic nephropathy
46.9
Unknown/unspeciﬁed 19.4
Glomerulonephritis 14.4
Cystic kidney diseases 7.1
Vasculitis 2.0
Other 8.0
CAKUT
Total 2.2 100
Neurogenic PN 5.6
Obstructive PN 22.9
Reﬂux PN 41.9
Hypoplasia 17.3
Dysplasia 12.3
RRT modality (%)
Hemodialysis 80.2 61.5
Peritoneal dialysis 17.2 26.1
Pre-emptive
transplantation
2.6 12.4
Mean age at
start RRT (yr)
All 61.4616.6 35.1621.0
Male patients 61.2616.5 33.1621.3
Female patients 61.7616.8 38.3620.1a
1990–1999 58.4616.7 32.9619.7
2000–2009 62.9616.3a 36.6621.5a
Neurogenic PN 41.8618.4b,c
Obstructive PN 34.1621.4c,d
Reﬂux PN 38.5618.7c,e
Hypoplasia 35.7623.9c,e
Dysplasia 22.1619.7c,f
Values expressed with a plus/minus sign are the mean 6 SD.
CAKUT, congenital anomalies of the kidney and urinary tract;
pmp, per million population; PN, pyelonephritis; RRT, renal
replacement therapy.
aSigniﬁcant difference between sex or time periods (P,0.001).
bSigniﬁcantly different from patients with obstructive PN,
reﬂux PN, hypoplasia, and dysplasia.
cSigniﬁcant difference (P,0.05).
dSigniﬁcantly different from patients with neurogenic PN,
reﬂux PN, hypoplasia, and dysplasia.
eSigniﬁcantly different from patients with neurogenic PN,
obstructive PN, and dysplasia.
fSigniﬁcantly different from patients with neurogenic,
obstructive, and reﬂux PN and hypoplasia.
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related population), with a second peak in the elderly (age
.70 years).
Figure 2B gives the cumulative percentage of patients
with CAKUT receiving RRT by disease category. Median
age at onset of RRT was 16 years in the dysplasia group, 32
years in those with hypoplasia, 29.5 years in the obstruc-
tive pyelonephritis group, 35 years in the reﬂux pyelone-
phritis group, and 39.5 years in patients with neurogenic
pyelonephritis.
The kidney transplantation rate strongly depended on
age. The fractions of patients with CAKUT who had
undergone transplantation within 10 years were 90.2%,
84.4%, 73.6%, 44.2%, and 6.5% for patients starting dialysis
at ages ,18, 18–34, 35–49, 50–64, and .65 years, respec-
tively.
The rate of preemptive kidney transplantation (12.4%
overall) was highest in patients with renal dysplasia
(23.4%) and lowest in those with neurogenic pyelonephritis
(4.2%). This difference remained signiﬁcant after adjust-
ment for sex and age at start of RRT (P=0.001).
Patient Survival during RRT
The overall 10-year patient survival rates were 92%,
89.5%, 74.7%, 47%, and 10.4% in patients with CAKUTwho
started RRT at ages ,18, 18–34, 35–49, 50–64, and $65
years, respectively. After adjustment for age, sex, RRT mo-
dality, time period of RRT, and country of origin, patient
survival during RRT was associated with the type of un-
derlying renal disease. The risk for death was highest in
patients with neurogenic pyelonephritis, intermediate
in those with renal dysplasia, and lowest in patients
with renal hypoplasia and obstructive or reﬂux pyelone-
phritis (Table 2 and Figure 3). The causes of death differed
between patients with CAKUT and matched patients with-
out CAKUT: Fewer of the former died of cardiovascular
causes (0.85/100 person-years for CAKUT versus 1.10 per
100 person-years for non-CAKUT) (Table 3). Within the
CAKUT group, patients with neurogenic pyelonephritis
were at increased risk for dying of cardiovascular disease,
infection, and other or unknown causes compared with the
other subcategories. Patients with renal hypoplasia had a
two-fold increase in risk for death due to cardiovascular
disease compared with patients in the dysplasia group
(1.02 versus 0.47 cases per 100 person-years) (Table 3).
Analysis of the results separately for death with dialysis
versus death with transplantation showed that directions
of differences in causes of death between the groups were
very similar, although the risk for death was much lower
for patients who underwent transplantation (Table 3).
Competing risk analysis demonstrated that patients with
CAKUT starting dialysis had a similar likelihood of
receiving a kidney transplant within 10 years as patients
without CAKUT (69.5% versus 66% after 10 years; P=0.14)
but a signiﬁcantly lower risk for death (23.6% versus 29.2%
at 10 years; P,0.001). The CAKUT subgroup with neuro-
genic pyelonephritis were less likely to receive a transplant
(41.9%; P=0.001 versus other CAKUT patients) and more
likely to die (41.5%; P=0.001 versus other CAKUT patients)
(Figure 4, A–C).
Graft Survival
Figure 5 gives the competing risk analysis for renal allo-
graft (Figure 5A) and patient survival (Figure 5B) within the
ﬁrst 10 years after renal transplantation. In patients with
CAKUT, the outcome with respect to graft (P=0.02) and
patient (P=0.007) survival was superior comparedwith out-
comes of patients without CAKUT, resulting in a higher
probability that patients with CAKUT would be alive
with a functioning graft after 10 years (67.1% versus
61.6%; P,0.001). In the Cox proportional hazard analysis,
the only factor predicting graft survival in the CAKUT pop-
ulation was the treatment time period (improved outcome
Table 2. Proportional hazard analysis for patient mortality on renal replacement therapy and renal graft loss in patients with
congenital anomalies of the kidney and urinary tract in the European Renal Association-European Dialysis and Transplant Association
Registry
Variable
Patient Mortality with RRT Graft Loss
HR (95% CI) P Value HR (95% CI) P Value
CAKUT category
Neurogenic PN 1.66 (1.24–2.21) 0.006 1.32 (0.93–1.87) 0.12
Obstructive PN 0.74 (0.56–0.99) 0.04 0.95 (0.74–1.22) 0.68
Reﬂux PN 0.75 (0.57–0.98) 0.04 1.03 (0.79–1.32) 0.85
Hypoplasia 0.73 (0.54–1.00) 0.05 1.04 (0.77–1.40) 0.81
Dysplasia 1.00 1.00
RRT modality at start
Hemodialysis 1.56 (1.04–2.33) 0.03 1.02 (0.81–1.28) 0.89
Peritoneal dialysis 1.29 (0.85–1.96) 0.23 0.89 (0.69–1.14) 0.37
Pre-emptive transplantation 1.00 1.00
Age 1.06 (1.06–1.06) ,0.001 1.00 (1.00–1.01) 0.39
Female sex 1.09 (0.95–1.25) 0.24 1.08 (0.92–1.26) 0.37
Period after 2000 0.98 (0.86–1.13) 0.81 0.78 (0.65–0.93) 0.01
RRT, renal replacement therapy; HR, hazard ratio; CI, conﬁdence interval; CAKUT, congenital anomalies of the kidney and urinary
tract; PN, pyelonephritis.
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in the more recent period), whereas CAKUT subcategory,
initial RRTmodality, age at kidney transplantation, and sex
did not have a signiﬁcant effect on transplantation outcome
(Table 2).
Supplemental Table 1, part of the online Appendix, com-
pares patient and graft survival of the total CAKUT cohort
and CAKUT patients excluding those who have neurogenic
pyelonephritis with survival in the total RRT population,
age-matched RRT patients, and RRT patients excluding
those with recurrent kidney diseases and diabetes.
Discussion
Limited information exists on the long-term natural
course of CKD due to CAKUT. Epidemiologic information
on the prevalence of congenital anomalies (including renal
and urinary malformations) has been provided by the
European Surveillance of Congenital Abnormalities Reg-
istry (14), covering almost 30% of the European birth pop-
ulation. However, no information on the postnatal course
of these patients is available. Although a few single-center
studies (10,11) and a single national registry (2) have as-
sessed the course of CKD in children with CAKUT, we
believe that our study is the ﬁrst to provide information
on the timing and outcomes of RRT in the individual phe-
notypic categories of CAKUT across the entire age range.
Because comprehensive population-based data on all pa-
tients with CAKUT are not available, our analysis was
limited to patients who progress to ESRD at any point
during their lifetime. Hence, we cannot draw any conclu-
sions regarding patients with milder forms of CAKUT
who never require RRT. Still, our analysis of .4700 pa-
tients from 12 European countries who started RRT during
the past two decades revealed several novel and remark-
able insights regarding the natural course of this group of
patients with rare kidney and urinary tract diseases.
Although the incidence of RRT was expectedly greater
during childhood, it was surprising to note that more than
two thirds of the patients progressed to ESRD at adult age,
and 50%did not require RRTbefore the fourth decade of life.
These ﬁgures are probably underestimations because an
unknown number of adults with CAKUT entering ESRD
programswithout apediatric history of renal diseasemaybe
misclassiﬁed as having CKD of “unspeciﬁed” or “other”
origin. Indeed, adult CKD and ESRD registries usually
Figure 3. | Patient survival during renal replacement therapy in
patients with congenital anomalies of the kidney and urinary tract
(CAKUT) from the European Renal Association-European Dialysis
and Transplant Association Registry. Findings are shown by CAKUT
category and for all patients without CAKUT.
Table 3. Mortality rate due to specific causes in patients without congenital anomalies of the kidney and urinary tract by treatment
modality
Variable
Mortality Rate by Cause of Death (per 100 Person-Years)
CVD Cancer Infection Other Unknown
Dialysis
Non-CAKUT 3.72a 0.68 1.49 2.09 1.87
CAKUT 2.05 0.51 1.28 1.62 1.51
Neurogenic PN 2.82b 0.45 2.12b 3.27b 2.25b
Obstructive PN 2.04 0.65 1.26 1.18 1.26
Reﬂux PN 1.86 0.45 1.07 1.55 1.55
Hypoplasia 2.79c 0.47 0.85 1.40 1.47
Dysplasia 0.72 0.52 1.45 0.83 1.24
Post-transplantation
Non-CAKUT 0.23 0.13 0.22 0.25 0.25
CAKUT 0.13 0.14 0.15 0.13 0.20
Neurogenic PN 0.41 0.10 0.51 0.41 0.61
Obstructive PN 0.12 0.10 0.02 0.06 0.14
Reﬂux PN 0.10 0.18 0.18 0.12 0.27
Hypoplasia 0.05 0.09 0.14 0.14 0.14
Dysplasia 0.16 0.16 0.16 0.16 0.04
CVD, cardiovascular disease; CAKUT, congenital anomalies of the kidneys and urinary tract; PN, pyelonephritis.
aSigniﬁcantly different from the CAKUT group
bWithin the CAKUT group: signiﬁcantly different from the dysplasia subgroup (P,0.05).
cWithin the CAKUT group: signiﬁcantly different from the other CAKUT subgroups (P,0.05).
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report 20%–27% of patients without a speciﬁed renal diag-
nosis, compared with less than 5% in pediatric registries
(1,15). In our data, 11.4% of the renal diagnoses among pa-
tients age ,20 years were classiﬁed as “unknown” or
“other,” comparedwith 19.6% among those.18 years. Fur-
thermore, we did not include patients with “pyelonephritis,
cause not speciﬁed” and “pyelonephritis due to other
cause,” which are slightly more often coded for adults
than for children and might include patients with con-
genital renal abnormalities as well.
Our ﬁndings suggest that in patients with a congenital
reduction in nephron mass, CKD progression due to
ongoing loss of remnant nephrons is probably a lifelong
process. In this respect, CAKUT disorders may be a
fascinating “experiment of nature” with which to study
the mechanisms leading to progressive nephron loss in
the absence of confounding immunologic and vascular
pathomechanisms, which are major effectors of disease
progression in most adult nephropathies.
Developed in the early 1970s, the ERA-EDTA disease
codes (6) partly reﬂect outdated pathophysiologic con-
cepts, such as the exclusive association of ESRD in the
presence of reﬂux-associated, obstructive, or neurogenic
urinary tract abnormalities with “pyelonephritis.” Ample
experimental and clinical evidence suggests that renal
function is commonly reduced at birth in patients with
urinary tract malformation, secondary to a common un-
derlying genetic abnormality or to early intrauterine uri-
nary tract obstruction altering kidney development (16,17).
Hence, bilateral renal hypoplasia or dysplasia is a far more
likely cause of ESRD in most RRT patients classiﬁed as
having “pyelonephritis” due to obstruction, reﬂux, or neu-
rogenic bladder disorder, even more so as antibiotic pro-
phylaxis and early corrective urologic surgery have greatly
reduced the incidence of upper urinary tract infections in
this population in the past three decades (18,19). The up-
coming release of new ERA-EDTA disease codes might
provide a more appropriate clinical and pathophysiologic
classiﬁcation of kidney diseases. However, for this retro-
spective analysis we were required to analyze the original
EDTA disease codes in an approximative manner.
In the context of these changed ontologic concepts, the
biphasic pattern of RRT incidence observed in the ﬁrst two
decades of life in patientswith obstructive nephropathy and
isolated renal dysplasia, with a dip around age 5–9 years, is
consistent with the notion that early renal survival depends
on the severity of renal dysplasia (10). Although children
with severe dysplastic kidney disease require RRT from
early infancy, those with less severe malformations charac-
teristically undergo a transient period of stable or even in-
creasing GFR resulting from compensatory hypertrophy of
the remnant functioning nephrons. The functional “reserve”
seems to be lowest in children with isolated renal dysplasia
or hypoplasia, in whom RRT incidence peaks again at 5–14
years, whereas childrenwith associated urinary tract abnor-
malities more frequently progress to ESRD around 15–25
years of age, with a spread into mid-adult life. A third
peak of RRT incidence observed in elderly patients, mainly
with obstructive nephropathies, may indicate admixture of
acquired disorders in this age group.
The sharp increase in RRT incidence observed around
puberty is in accordance with data from a population-based
pediatric CKD registry comprising 1200 children in Italy (2 )
and was also noted in the prospective Effect of Strict Blood
Pressure Control and ACE Inhibition on the Progression
of CRF in Pediatric Patients (ESCAPE) trial (20). It is inter-
esting to speculate whether this may be due to an increasing
discrepancy between body size and functional nephron
mass or whether the emerging production of sex steroid
hormones at this age may inﬂuence renal survival. In this
context, observations in patients with polycystic kidney dis-
ease (21), the Reduction of Endpoints in NIDDM with the
Figure 4. | Outcomeof patients receiving renal replacement therapy.
Competing risk analysis for patient survival and kidney transplantation
during dialysis, comparing (A) patients with other primary renal dis-
eases matched for age, sex, country, year of start of renal replacement
therapy, and treatment modality at start with (B) all patients with
congenital anomalies of the kidney and urinary tract (CAKUT) and (C)
patients with neurogenic pyelonephritis from the European Renal
Association-European Dialysis and Transplant Association Registry.
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Angiotensin II Antagonist Losartan (RENAAL) study (22),
and a Canadian CKD study (23) have suggested that male
sex might be a general risk factor for CKD progression. At
ﬁrst glance, our ﬁnding of earlier RRT onset inmale patients
appears to support this notion. However, the sex difference
was largely conﬁned to urinary tract abnormalities. It is pos-
sible that amajor fraction ofmale patients in these categories
hadposterior urethral valves, amale-limited condition often
associated with particularly severe renal dysplasia. In keep-
ing with a major effect of sex-speciﬁc underlying kidney
diseases on renal survival, a recent single-center CAKUT
study from Italy showed that male sex predicted a shorter
renal survival by univariate analysis but not after adjust-
ment for diagnosis categories (11).
An issue of great concern for parents of children born
with severe CAKUT is the uncertainty about the patients’
long-term well-being and survival. Mortality from
childhood-onset ESRD is markedly increased even among
children (24), although most survive into adult life. This
study provides several important pieces of information about
late outcomes of CAKUT. Besides the fact that most patients
who need to start RRT will not do so before adulthood, the
survival of patients with CAKUT receiving RRT is slightly
better than that of age-matched patients with other underly-
ing kidney diseases, such as type 1 diabetic nephropathy and
other acquired and inherited glomerulopathies. This may be
explained by the frequently retained urine production in pa-
tients with dysplastic kidneys, even on dialysis, and the con-
secutively lower incidence of ﬂuid overload, hypertension,
and metabolic abnormalities in patients with CAKUT com-
pared with those who have other diseases leading to ESRD.
Indeed, patients with CAKUT were less likely to die of car-
diovascular causes than were those without CAKUT.
An exception to this rule was the subgroup of patients
with ESRD related to neurogenic bladder abnormalities,
who showed markedly poorer patient survival. These
patients often need some form of urinary diversion (con-
duit or reservoir), which is associated with a higher risk for
chronic and potentially invasive infections, an increased
risk for malignancies, and a less favorable outcome after
renal transplantation (25,26). In addition, these patients
may have various neurologic comorbid conditions and
complications that could affect their long-term survival.
Finally, after adjustment for age, sex, and disease sub-
type, patients with CAKUT had a better chance of survival
while undergoing peritoneal dialysis compared with he-
modialysis. This ﬁnding is consistent with previous ﬁnd-
ings in the ERA-EDTA Registry (27). In a large Canadian
study (28) and in the U.S. Renal Data System (29), younger
nondiabetic patients without comorbidity also had a sur-
vival beneﬁt while receiving peritoneal dialysis, whereas
no difference was seen in the total RRT cohort.
In conclusion, this study demonstrates that the tradi-
tional view of CAKUT as a rare pediatric kidney disorder of
concern only to pediatric nephrologists and urologists
should be revised. Many patients with moderate to severe
renal hypoplasia or dysplasia and stable CKD during
childhood progress to ESRD requiring RRT during adult-
hood. It will be important to develop effective transition
strategies from pediatric to adult nephrology service, aware-
ness of disease-speciﬁc risks and conditions, and continued
good-quality medical care for this group of patients, who
constitute the main cause of pediatric CKD but only a small
fraction of the adult CKD and ESRD population. Further-
more, this study identiﬁes important differences in the
long-term phenotypic evolution of different subgroups of
CAKUT. Efforts should be made to improve disease clas-
siﬁcation by comprehensive reference to the clinical, genetic,
and molecular features of the disorders. More appropriate
disease classiﬁcation, ideally combined with life-long pa-
tient follow-up in dedicated registries, will contribute to
improved prognostic counseling and personalized disease
management among patients with congenital kidney mal-
formations (30).
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